HomeAI · summaries
Storia in 3 fonti
Once-daily GLP-1/GIP dual agonist lowers HbA1c, weight in type 1 diabetes
NEW ORLEANS — A once-daily GLP-1/GIP dual agonist reduced HbA1c and body weight at 16 weeks among adults with type 1 diabetes, according to findings from a phase 2 trial presented at the American Diabetes Association Scientific Sessions.Acmopatide (Roche), formerly known as CT-868, delivered a wide range of benefits among people with type 1 diabetes. Beyond improvements in HbA1c and body
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control
First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control
- ·
endpoints.news
Roche’s incretin shot works in mid-stage trial in type 1 diabetes
Roche's acmopatide cut A1C by 0.34% and reduced insulin use by 15% in a Phase 2 trial in type 1 diabetes patients with obesity.
